TET2 and neoplasm: Global genomic reduction in 5hmC, potentially mediated by loss of TET2 function, has been reported as an independent adverse prognostic marker for OS in a cohort of NSCLC patients (n = 208), with low 5hmC levels significantly associated with large tumor size and lymph node metastasis.